Abstract
The use of biomarkers has recently supported the association between Alzheimer's disease (AD) pathology and the logopenic variant of primary progressive aphasia (PPA). We aim to investigate possible differences in cerebrospinal fluid (CSF) biomarker concentrations in the three PPA variants, and to assess any agreement between CSF biomarkers and (18)F-florbetapir PET. A group of 10 PPA were retrospectively enrolled. Patients with logopenic variant (lvPPA) showed different levels of Aβ1-42 and p-tau compared to nonfluent/agrammatic and semantic variants (nfv/svPPA). All nfv/svPPA patients had negative amyloid PET. Among the lvPPA group, a negative amyloid PET was found only in one patient, who was also the only one to display a normal CSF. Thus, this small cohort appeared to display an excellent agreement between CSF and (18)F-florbetapir PET and suggest that these examinations may have the same validity in detecting in vivo evidence of AD pathology in PPA clinical variants.
| Original language | English |
|---|---|
| Pages (from-to) | 282-284 |
| Number of pages | 3 |
| Journal | Alzheimer Disease and Associated Disorders |
| Volume | 33 |
| Issue number | (3) |
| Early online date | Jan 10 2019 |
| DOIs | |
| Publication status | Published - 2019 |
Fingerprint
Cite this
Role of Cerebrospinal Fluid Biomarkers and (18)F-florbetapir PET Imaging in the Diagnosis of Primary Progressive Aphasia : A Retrospective Analysis. / Perini, Giulia; Cotta Ramusino, Matteo; Sinforiani, Elena; Franciotta, Diego; Trifirò, Giusppe; Ceroni, Mauro; Costa, Alfredo.
In: Alzheimer Disease and Associated Disorders, Vol. 33, No. (3), 2019, p. 282-284.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Role of Cerebrospinal Fluid Biomarkers and (18)F-florbetapir PET Imaging in the Diagnosis of Primary Progressive Aphasia
T2 - A Retrospective Analysis
AU - Perini, Giulia
AU - Cotta Ramusino, Matteo
AU - Sinforiani, Elena
AU - Franciotta, Diego
AU - Trifirò, Giusppe
AU - Ceroni, Mauro
AU - Costa, Alfredo
PY - 2019
Y1 - 2019
N2 - The use of biomarkers has recently supported the association between Alzheimer's disease (AD) pathology and the logopenic variant of primary progressive aphasia (PPA). We aim to investigate possible differences in cerebrospinal fluid (CSF) biomarker concentrations in the three PPA variants, and to assess any agreement between CSF biomarkers and (18)F-florbetapir PET. A group of 10 PPA were retrospectively enrolled. Patients with logopenic variant (lvPPA) showed different levels of Aβ1-42 and p-tau compared to nonfluent/agrammatic and semantic variants (nfv/svPPA). All nfv/svPPA patients had negative amyloid PET. Among the lvPPA group, a negative amyloid PET was found only in one patient, who was also the only one to display a normal CSF. Thus, this small cohort appeared to display an excellent agreement between CSF and (18)F-florbetapir PET and suggest that these examinations may have the same validity in detecting in vivo evidence of AD pathology in PPA clinical variants.
AB - The use of biomarkers has recently supported the association between Alzheimer's disease (AD) pathology and the logopenic variant of primary progressive aphasia (PPA). We aim to investigate possible differences in cerebrospinal fluid (CSF) biomarker concentrations in the three PPA variants, and to assess any agreement between CSF biomarkers and (18)F-florbetapir PET. A group of 10 PPA were retrospectively enrolled. Patients with logopenic variant (lvPPA) showed different levels of Aβ1-42 and p-tau compared to nonfluent/agrammatic and semantic variants (nfv/svPPA). All nfv/svPPA patients had negative amyloid PET. Among the lvPPA group, a negative amyloid PET was found only in one patient, who was also the only one to display a normal CSF. Thus, this small cohort appeared to display an excellent agreement between CSF and (18)F-florbetapir PET and suggest that these examinations may have the same validity in detecting in vivo evidence of AD pathology in PPA clinical variants.
U2 - 10.1097/WAD.0000000000000289
DO - 10.1097/WAD.0000000000000289
M3 - Article
C2 - 30640253
VL - 33
SP - 282
EP - 284
JO - Alzheimer Disease and Associated Disorders
JF - Alzheimer Disease and Associated Disorders
SN - 0893-0341
IS - (3)
ER -